Publications by authors named "Emily Wearne"

Claim this Profile
U
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.
Elizabeth S Duke, Diana Bradford, Arup K Sinha, Pallavi S Mishra-Kalyani, Catherine C Lerro, Emily Wearne

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Katie Chon, Erin Larkins, Somak Chatterjee, Pallavi S Mishra-Kalyani, Stephanie Aungst, Emily Wearne

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Elizabeth S Duke, Liza Stapleford, Nicole Drezner, Anup K Amatya, Pallavi S Mishra-Kalyani, Emily Wearne

Clin Cancer Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
Elizabeth S Duke, Amy K Barone, Somak Chatterjee, Pallavi S Mishra-Kalyani, Yuan-Li Shen, Emily Wearne

Clin Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
Erica C Nakajima, Nicole Drezner, Xiaoxue Li, Pallavi S Mishra-Kalyani, Yajun Liu, Emily Wearne

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With Gene Mutations or Fusions.
Janice Kim, Diana Bradford, Erin Larkins, Lee H Pai-Scherf, Somak Chatterjee, Emily Wearne

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: TAS-102.
Leigh Marcus, Steven J Lemery, Sachia Khasar, Emily Wearne, Whitney S Helms

Clin Cancer Res· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An FDA oncology analysis of immune activating products and first-in-human dose selection.
Haleh Saber, Ramadevi Gudi, Michael Manning, Emily Wearne, John K Leighton

Regul Toxicol Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis